

0590  
1012

OIPE

#2

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/929,924

DATE: 11/27/2001

TIME: 12:47:06

Input Set : N:\Crf3\RULE60\09929924.txt

Output Set: N:\CRF3\11272001\I929924.raw

ENTERED

4 <110> APPLICANT: Center, David M.  
5 Cruickshank, William W.  
6 Kornfeld, Hardy  
8 <120> TITLE OF INVENTION: IL-16 ANTAGONISTS  
10 <130> FILE REFERENCE: Research Corporation Tech., Inc.  
12 <140> CURRENT APPLICATION NUMBER: 09/929,924  
13 <141> CURRENT FILING DATE: 2001-08-15  
15 <150> PRIOR APPLICATION NUMBER: 09/368,632  
16 <151> PRIOR FILING DATE: 1999-08-05  
18 <160> NUMBER OF SEQ ID NOS: 41  
20 <170> SOFTWARE: PatentIn Ver. 2.1  
22 <210> SEQ ID NO: 1  
23 <211> LENGTH: 4  
24 <212> TYPE: PRT  
25 <213> ORGANISM: Artificial Sequence  
27 <220> FEATURE:  
28 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide  
30 <220> FEATURE:  
31 <221> NAME/KEY: UNSURE  
32 <222> LOCATION: (1)  
33 <223> OTHER INFORMATION: Xaa can be any amino acid  
35 <220> FEATURE:  
36 <221> NAME/KEY: UNSURE  
37 <222> LOCATION: (4)  
38 <223> OTHER INFORMATION: Xaa can be any amino acid  
40 <400> SEQUENCE: 1  
W--> 41 Xaa Lys Lys Xaa  
42 1  
45 <210> SEQ ID NO: 2  
46 <211> LENGTH: 4  
47 <212> TYPE: PRT  
48 <213> ORGANISM: Artificial Sequence  
50 <220> FEATURE:  
51 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide  
53 <400> SEQUENCE: 2  
54 Cys Leu Leu Ser  
55 1  
58 <210> SEQ ID NO: 3  
59 <211> LENGTH: 6  
60 <212> TYPE: PRT  
61 <213> ORGANISM: Artificial Sequence  
63 <220> FEATURE:  
64 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide  
66 <220> FEATURE:  
67 <221> NAME/KEY: UNSURE  
68 <222> LOCATION: (1)..(3)  
69 <223> OTHER INFORMATION: Xaa can be any amino acid

## RAW SEQUENCE LISTING

DATE: 11/27/2001

PATENT APPLICATION: US/09/929,924

TIME: 12:47:06

Input Set : N:\Crf3\RULE60\09929924.txt

Output Set: N:\CRF3\11272001\I929924.raw

```

71 <220> FEATURE:
72 <221> NAME/KEY: UNSURE
73 <222> LOCATION: (6)
74 <223> OTHER INFORMATION: Xaa can be any amino acid
76 <400> SEQUENCE: 3
W--> 77 Xaa Xaa Xaa Leu Leu Xaa
78   1           5
81 <210> SEQ ID NO: 4
82 <211> LENGTH: 6
83 <212> TYPE: PRT
84 <213> ORGANISM: Artificial Sequence
86 <220> FEATURE:
87 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
89 <400> SEQUENCE: 4
90 Trp Gln Cys Leu Leu Ser
91   1           5
94 <210> SEQ ID NO: 5
95 <211> LENGTH: 6
96 <212> TYPE: PRT
97 <213> ORGANISM: Artificial Sequence
99 <220> FEATURE:
100 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
102 <400> SEQUENCE: 5
103 Trp Gln Ala Leu Leu Ser
104   1           5
107 <210> SEQ ID NO: 6
108 <211> LENGTH: 6
109 <212> TYPE: PRT
110 <213> ORGANISM: Artificial Sequence
112 <220> FEATURE:
113 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
115 <400> SEQUENCE: 6
116 Trp Ala Cys Leu Leu Ser
117   1           5
120 <210> SEQ ID NO: 7
121 <211> LENGTH: 6
122 <212> TYPE: PRT
123 <213> ORGANISM: Artificial Sequence
125 <220> FEATURE:
126 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
128 <400> SEQUENCE: 7
129 Trp Gln Cys Glu Leu Ser
130   1           5
133 <210> SEQ ID NO: 8
134 <211> LENGTH: 6
135 <212> TYPE: PRT
136 <213> ORGANISM: Artificial Sequence
138 <220> FEATURE:
139 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/929,924

DATE: 11/27/2001

TIME: 12:47:06

Input Set : N:\Crf3\RULE60\09929924.txt

Output Set: N:\CRF3\11272001\I929924.raw

```

141 <220> FEATURE:
142 <221> NAME/KEY: UNSURE
143 <222> LOCATION: (1)
144 <223> OTHER INFORMATION: Xaa can be any amino acid
146 <220> FEATURE:
147 <221> NAME/KEY: UNSURE
148 <222> LOCATION: (3)
149 <223> OTHER INFORMATION: Xaa can be any amino acid
151 <220> FEATURE:
152 <221> NAME/KEY: UNSURE
153 <222> LOCATION: (5)..(6)
154 <223> OTHER INFORMATION: Xaa can be any amino acid
156 <400> SEQUENCE: 8
W--> 157 Xaa Val Xaa Val Xaa Xaa
158     1           5
161 <210> SEQ ID NO: 9
162 <211> LENGTH: 6
163 <212> TYPE: PRT
164 <213> ORGANISM: Artificial Sequence
166 <220> FEATURE:
167 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
169 <400> SEQUENCE: 9
170 Val Val Gln Val Val Ala
171     1           5
174 <210> SEQ ID NO: 10
175 <211> LENGTH: 6
176 <212> TYPE: PRT
177 <213> ORGANISM: Artificial Sequence
179 <220> FEATURE:
180 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
182 <400> SEQUENCE: 10
183 Val Lys Gln Val Val Ala
184     1           5
187 <210> SEQ ID NO: 11
188 <211> LENGTH: 6
189 <212> TYPE: PRT
190 <213> ORGANISM: Artificial Sequence
192 <220> FEATURE:
193 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
195 <400> SEQUENCE: 11
196 Val Val Gln Lys Val Ala
197     1           5
200 <210> SEQ ID NO: 12
201 <211> LENGTH: 16
202 <212> TYPE: PRT
203 <213> ORGANISM: Artificial Sequence
205 <220> FEATURE:
206 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
208 <400> SEQUENCE: 12

```

## RAW SEQUENCE LISTING

DATE: 11/27/2001

PATENT APPLICATION: US/09/929,924

TIME: 12:47:06

Input Set : N:\Crf3\RULE60\09929924.txt

Output Set: N:\CRF3\11272001\I929924.raw

```

209 Gly Met Trp Gln Cys Leu Leu Ser Asp Ser Gly Gln Val Leu Leu Glu
210   1           5           10           15
213 <210> SEQ ID NO: 13
214 <211> LENGTH: 8
215 <212> TYPE: PRT
216 <213> ORGANISM: Artificial Sequence
218 <220> FEATURE:
219 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
221 <400> SEQUENCE: 13
222 Gly Met Trp Gln Cys Leu Leu Ser
223   1           5
226 <210> SEQ ID NO: 14
227 <211> LENGTH: 12
228 <212> TYPE: PRT
229 <213> ORGANISM: Artificial Sequence
231 <220> FEATURE:
232 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
234 <400> SEQUENCE: 14
235 Thr Gly Leu Trp Gln Cys Leu Leu Ser Glu Gly Asp
236   1           5           10
239 <210> SEQ ID NO: 15
240 <211> LENGTH: 12
241 <212> TYPE: PRT
242 <213> ORGANISM: Artificial Sequence
244 <220> FEATURE:
245 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
247 <400> SEQUENCE: 15
248 Val Ser Glu Glu Gln Lys Val Val Gln Val Val Ala
249   1           5           10
252 <210> SEQ ID NO: 16
253 <211> LENGTH: 73
254 <212> TYPE: PRT
255 <213> ORGANISM: Artificial Sequence
257 <220> FEATURE:
258 <223> OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide
260 <400> SEQUENCE: 16
261 Asn Leu Thr Cys Glu Val Trp Gly Pro Thr Ser Pro Lys Leu Met Leu
262   1           5           10           15
264 Ser Leu Lys Leu Glu Asn Lys Glu Ala Lys Val Ser Lys Arg Glu Lys
265           20           25           30
267 Ala Val Trp Val Leu Asn Pro Glu Ala Gly Met Trp Gln Cys Leu Leu
268           35           40           45
270 Ser Asp Ser Gly Gln Val Leu Leu Glu Ser Asn Ile Lys Val Leu Pro
271           50           55           60
273 Thr Trp Ser Thr Pro Val Gln Pro Met
274   65           70
277 <210> SEQ ID NO: 17
278 <211> LENGTH: 72
279 <212> TYPE: PRT

```

## RAW SEQUENCE LISTING

DATE: 11/27/2001

PATENT APPLICATION: US/09/929,924

TIME: 12:47:06

Input Set : N:\Crf3\RULE60\09929924.txt

Output Set: N:\CRF3\11272001\I929924.raw

280 &lt;213&gt; ORGANISM: Artificial Sequence

282 &lt;220&gt; FEATURE:

283 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide

285 &lt;400&gt; SEQUENCE: 17

286 Thr Leu Thr Cys Glu Val Met Gly Pro Thr Ser Pro Lys Met Arg Leu

287 1 5 10 15

289 Thr Leu Lys Gln Glu Asn Gln Glu Ala Arg Val Ser Glu Glu Gln Lys

290 20 25 30

292 Val Val Gln Val Val Ala Pro Glu Thr Gly Leu Trp Gln Cys Leu Leu

293 35 40 45

295 Ser Glu Gly Asp Lys Val Lys Met Asp Ser Arg Ile Gln Val Leu Ser

296 50 55 60

298 Arg Gly Val Asn Gln Thr Val Phe

299 65 70

302 &lt;210&gt; SEQ ID NO: 18

303 &lt;211&gt; LENGTH: 6

304 &lt;212&gt; TYPE: PRT

305 &lt;213&gt; ORGANISM: Artificial Sequence

307 &lt;220&gt; FEATURE:

308 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide

310 &lt;400&gt; SEQUENCE: 18

311 Val Ser Glu Glu Gln Lys

312 1 5

315 &lt;210&gt; SEQ ID NO: 19

316 &lt;211&gt; LENGTH: 6

317 &lt;212&gt; TYPE: PRT

318 &lt;213&gt; ORGANISM: Artificial Sequence

320 &lt;220&gt; FEATURE:

321 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide

323 &lt;400&gt; SEQUENCE: 19

324 Val Val Gln Val Val Ala

325 1 5

328 &lt;210&gt; SEQ ID NO: 20

329 &lt;211&gt; LENGTH: 12

330 &lt;212&gt; TYPE: PRT

331 &lt;213&gt; ORGANISM: Artificial Sequence

333 &lt;220&gt; FEATURE:

334 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide

336 &lt;400&gt; SEQUENCE: 20

337 Leu Ser Lys Gln Lys Met Val Ser Arg Glu Gly Thr

338 1 5 10

341 &lt;210&gt; SEQ ID NO: 21

342 &lt;211&gt; LENGTH: 6

343 &lt;212&gt; TYPE: PRT

344 &lt;213&gt; ORGANISM: Artificial Sequence

346 &lt;220&gt; FEATURE:

347 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:IL-16 antagonist peptide

349 &lt;400&gt; SEQUENCE: 21

350 Val Ala Pro Glu Thr Gly

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/929,924

DATE: 11/27/2001

TIME: 12:47:07

Input Set : N:\Crf3\RULE60\09929924.txt

Output Set: N:\CRF3\11272001\I929924.raw

L:41 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:77 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:157 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8